The Biomarkers Program will identify molecules with physiological relevance or that can be used as surrogate indicators along with diagnostic and neuroimaging criteria to further improve patient assessment and personalize treatment options when applicable. Information from both the Biomarkers and Diagnostics Programs will be important for classification of patients into future clinical trials and to monitor outcome, along with the Rehabilitation and Evaluation Program.
Principal Investigator
Title
Raymond Dionne
Biomarkers-Driven Experimental Therapeutics
Michael Iadarola
Neuro-Glial Antibodies in TBI
Hyung-suk Kim
Characterization of the human blood genomic response to TBI
Fabio Leonessa
Plasma biomarkers of blast-related brain edema
Greg Mueller
Evaluation of Putative Biomarkers in TBI
Harvey Pollard
Proinflammatory Biomarkers for Mild Blast TBI
Esther Sternberg
Non-invasive Sweat Patch Technology for Determination of Neuroimmune Biomarkers
Amina Woods
Brain Region Specific Biomarkers in Animal Models of TBI
Amina Woods
Evaluating a Novel Peptide Therapy for TBI; a Biomarkers-Based Approach
Ramon Diaz-Arrastia
Administration of recombinant erythropoietin to improve neovascularization and decrease neuroinflammation after TBI.
Ann Scher
One-Carbon Metabolism Markers in Post-Traumatic Epilepsy